ISHAN GHOSH
SMA Type 2
Campaign Story
SMA Type 2 is a genetic neuromuscular disorder caused by the survival motor neuron gene (SMN1) mutation. Because of this mutation, the body does not produce enough SMN protein, which is essential for motor neurons. Without it, the nerves controlling movement weaken over time. 👶 Who Gets SMA Type 2? Symptoms usually appear between 6–18 months of age. Children with SMA Type 2 can sit without support, but cannot stand or walk independently. 🧠Causes Mutation or deletion in the SMN1 gene. Inherited in an autosomal recessive pattern (both parents carry the gene). 🩺 Symptoms Motor Symptoms Muscle weakness (especially legs) Trouble standing or walking Tremors (especially in hands) Scoliosis (curved spine) Joint problems (contractures) Difficulty lifting arms above shoulders Other Symptoms Breathing weakness (mild to moderate) Difficulty coughing out mucus Swallowing issues (sometimes) Fatigue during physical activity 🧪 Diagnosis Doctors confirm SMA Type 2 using: Genetic testing (SMN1 gene study) EMG (electromyography) Muscle function assessments CK (creatine kinase) levels (sometimes slightly elevated) 💊 Treatment Options (Modern & Effective) While SMA has no cure, new treatments significantly improve strength and lifespan. 1. Spinraza (Nusinersen) First FDA-approved SMA drug Delivered by spinal injection Increases SMN protein production 2. Zolgensma (Gene Therapy) One-time IV gene therapy Replaces faulty SMN1 gene Mostly for infants under 2 years 3. Evrysdi (Risdiplam) Daily oral medicine Increases SMN protein levels Approved for adults and children over 2 months 4. Supportive Therapies Physiotherapy Respiratory therapy Orthopedic support (braces, scoliosis treatment) Nutritional management 🧬 Life Expectancy With modern treatments, life expectancy for SMA Type 2 is near-normal. Most people: Live into adulthood Continue education and career Maintain independence with mobility aids 🧡 How It Affects Daily Life People with SMA Type 2 may use: Wheelchair for mobility Standing frames Bracing for spine Respiratory support during sleep But with therapy and medications, they can lead active, productive lives. 🧒 Prognosis Slow progression over years Early treatment improves motor function significantly New medicines greatly reduce complications
- SMA Type 2
- is a genetic neuromuscular disorder caused by the survival motor neuron gene (SMN1) mutation.
Campaign Goal
0.4% Funded₹20,121.00
Raised₹5,000,000
Goal₹4,979,879.00 still needed
Your donation can make a difference!Scan to Donate
